A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung Cancer

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study

“…As single agents, cisplatin (CDDP), ifosfamide (IFX), mitomycin-C (MMC) and vindesine (VDS) achieve a 5-20% objective response rate in chemotherapy-naive patients (Sculier, 1984;Johnson, 1990). Recently, vinorelbine (VNR) showed interesting activity in a phase II study and in a large randomized trial (Depierre et al, 1991;Le Chevalier et al, 1994). Combination chemotherapy induces a response rate of 20-40%, and some authors have demonstrated that three-drug cisplatin-based regimens are more active and prolong survival compared with two-drug combinations (Crin6 et al, 1995).…”

Phase II Trial of Docetaxel in Asian Patients with Inoperable Stage III Non-Small Cell Lung Cancer

“…This is similar to the response rates we report in our study. Of the active agents in NSCLC, cisplatin has a response rate of 19% (17), and Table 2 Non-hematological toxicities -cycle 1 (n=35) newer agents such as gemcitabine have a response rate of 20% (18), paclitaxel 21% (19), and vinorelbine 27% (20). Accordingly, docetaxel certainly appears to be among the most active single agents in NSCLC.…”

New Agents in the Management of Non-Small-Cell Lung Cancer

“…Mild peripheral neuropathy has been observed at higher dose levels. 15 The excellent activity of vinorelbine against NSCLC has been demonstrated in phase II studies. French investigators reported an objective response rate of 29% in 78 chemotherapy-naive patients given a weekly vinorelbine dose of 30 mg/m 2 .…”